Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505088 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
A Phase 3 study, sponsored by Eyegate Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT01505088: Completed Phase 3 study, sponsored by Eyegate Pharmaceuticals.
NCT01505088 is a Phase 3 study that has completed, run by Eyegate Pharmaceuticals. The registered enrollment target is 193 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01505088, a Phase 3 study, has completed, sponsored by Eyegate Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Primary Outcome
Proportion of patients with ACC count of zero at Day 14
Interventions
- DRUG Placebo Eyedrops
- DRUG 40 mg/mL Dexamethasone phosphate ophthalmic solution
- DRUG Prednisolone Acetate (1%) Eyedrops
- DRUG 100 mM sodium citrate buffer solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
What the finished NCT01505088 record still lists
NCT01505088 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo Eyedrops is the first listed.
NCT01505088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01505088 about?
NCT01505088 is a clinical study titled "Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis". The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior seg...
What is the current status of trial NCT01505088?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2011-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01505088?
The interventions under investigation include: Placebo Eyedrops (DRUG), 40 mg/mL Dexamethasone phosphate ophthalmic solution (DRUG), Prednisolone Acetate (1%) Eyedrops (DRUG), 100 mM sodium citrate buffer solution (DRUG).
Who is sponsoring clinical trial NCT01505088?
This trial is sponsored by Eyegate Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01505088's enrollment target sits among peer trials
193 1397th of 2000 higher than 603 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia